158 related articles for article (PubMed ID: 22510345)
1. Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples.
Bertilsson H; Tessem MB; Flatberg A; Viset T; Gribbestad I; Angelsen A; Halgunset J
Clin Cancer Res; 2012 Jun; 18(12):3261-9. PubMed ID: 22510345
[TBL] [Abstract][Full Text] [Related]
2. Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.
Selnaes KM; Gribbestad IS; Bertilsson H; Wright A; Angelsen A; Heerschap A; Tessem MB
NMR Biomed; 2013 May; 26(5):600-6. PubMed ID: 23280546
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues.
Singh KK; Desouki MM; Franklin RB; Costello LC
Mol Cancer; 2006 Apr; 5():14. PubMed ID: 16595004
[TBL] [Abstract][Full Text] [Related]
4. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
Crehange G; Maingon P; Gauthier M; Parfait S; Cochet A; Mirjolet C; Bonnetain F; Cormier L; Brunotte F; Walker P
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e407-13. PubMed ID: 21605949
[TBL] [Abstract][Full Text] [Related]
5. Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.
Weis J; Ahlström H; Hlavcak P; Häggman M; Ortiz-Nieto F; Bergman A
Magn Reson Imaging; 2009 Jan; 27(1):87-93. PubMed ID: 18599244
[TBL] [Abstract][Full Text] [Related]
6. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.
Averna TA; Kline EE; Smith AY; Sillerud LO
J Urol; 2005 Feb; 173(2):433-8. PubMed ID: 15643195
[TBL] [Abstract][Full Text] [Related]
7. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.
Giskeødegård GF; Bertilsson H; Selnæs KM; Wright AJ; Bathen TF; Viset T; Halgunset J; Angelsen A; Gribbestad IS; Tessem MB
PLoS One; 2013; 8(4):e62375. PubMed ID: 23626811
[TBL] [Abstract][Full Text] [Related]
8. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues.
Swanson MG; Vigneron DB; Tabatabai ZL; Males RG; Schmitt L; Carroll PR; James JK; Hurd RE; Kurhanewicz J
Magn Reson Med; 2003 Nov; 50(5):944-54. PubMed ID: 14587005
[TBL] [Abstract][Full Text] [Related]
9. Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
Zbýň Š; Krššák M; Memarsadeghi M; Gholami B; Haitel A; Weber M; Helbich TH; Trattnig S; Moser E; Gruber S
Rofo; 2014 Jul; 186(7):698-702. PubMed ID: 24940925
[TBL] [Abstract][Full Text] [Related]
10. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H
Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
[TBL] [Abstract][Full Text] [Related]
12. Proton MR spectroscopy of the prostate.
Mueller-Lisse UG; Scherr MK
Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
[TBL] [Abstract][Full Text] [Related]
13. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
Hom JJ; Coakley FV; Simko JP; Lu Y; Qayyum A; Westphalen AC; Schmitt LD; Carroll PR; Kurhanewicz J
Radiology; 2007 Feb; 242(2):483-9. PubMed ID: 17179396
[TBL] [Abstract][Full Text] [Related]
14. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
van Dorsten FA; van der Graaf M; Engelbrecht MR; van Leenders GJ; Verhofstad A; Rijpkema M; de la Rosette JJ; Barentsz JO; Heerschap A
J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells.
Tsui KH; Chung LC; Wang SW; Feng TH; Chang PL; Juang HH
J Mol Endocrinol; 2013; 51(1):131-41. PubMed ID: 23709747
[TBL] [Abstract][Full Text] [Related]
16. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Glunde K; Jie C; Bhujwalla ZM
Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
[TBL] [Abstract][Full Text] [Related]
17. Cyclic adenosine 3',5'-monosphosphate mediate prolactin regulation of mitochondrial aconitase in human prostate carcinoma cells.
Juang HH
Mol Cell Endocrinol; 2004 Apr; 219(1-2):141-9. PubMed ID: 15149735
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
19. Effects of potassium-magnesium citrate supplementation on cytosolic ATP citrate lyase and mitochondrial aconitase activity in leukocytes: a window on renal citrate metabolism.
Tosukhowong P; Tungsanga K; Phongudom S; Sriboonlue P
Int J Urol; 2005 Feb; 12(2):140-4. PubMed ID: 15733107
[TBL] [Abstract][Full Text] [Related]
20. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma.
Andersen MK; Rise K; Giskeødegård GF; Richardsen E; Bertilsson H; Størkersen Ø; Bathen TF; Rye M; Tessem MB
Sci Rep; 2018 Sep; 8(1):14269. PubMed ID: 30250137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
